Cargando…

COVID-19 mRNA Vaccination Appears Safe in Pediatric Patients With A Hypersensitivity Reaction To PEGylated Escherichia Coli L-Asparaginase

Detalles Bibliográficos
Autores principales:	Wolfset, Nicole, Phillips, Charles, Stein, Madison, Rheingold, Susan, Heimall, Jennifer, Elgarten, Caitlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Mosby, Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804453/ http://dx.doi.org/10.1016/j.jaci.2021.12.576

Ejemplares similares

Management of adverse effects associated with pegylated Escherichia coli asparaginase on coagulation in the treatment of patients with NK/T-cell lymphoma
por: Yang, Jing, et al.
Publicado: (2022)

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Kim, Hyun Jee, et al.
Publicado: (2018)

Novel site-specific PEGylated L-asparaginase
por: Meneguetti, Giovanna Pastore, et al.
Publicado: (2019)

Correction: Novel site-specific PEGylated L-asparaginase
por: Meneguetti, Giovanna Pastore, et al.
Publicado: (2019)

Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia
por: Khalil, Alaeddin, et al.
Publicado: (2020)

PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review
por: Medawar, Camile Valle, et al.
Publicado: (2020)

HLA alleles associated with asparaginase hypersensitivity in Chinese children
por: Chua, Gilbert T., et al.
Publicado: (2021)

Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia
por: Avramis, Vassilios I, et al.
Publicado: (2006)

Cloning, expression, purification and characterisation of Erwinia carotovora L-asparaginase in Escherichia coli
por: Pourhossein, Meraj, et al.
Publicado: (2014)

SUPPRESSION OF MURINE LEUKEMIAS BY L-ASPARAGINASE : INCIDENCE OF SENSITIVITY AMONG LEUKEMIAS OF VARIOUS TYPES: COMPARATIVE INHIBITORY ACTIVITIES OF GUINEA PIG SERUML-ASPARAGINASE AND ESCHERICHIA COLI L-ASPARAGINASE
por: Boyse, Edward A., et al.
Publicado: (1967)

Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product
por: Schnuchel, Arndt, et al.
Publicado: (2023)

Allergic Reactions to E. coli Asparaginase are Associated with Decreased Asparaginase Activity in an Indonesian Pediatric Population with ALL
por: Sari, Nur Melani, et al.
Publicado: (2023)

Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors FcεRI and FcγRIII
por: Rathod, Sanjay, et al.
Publicado: (2019)

Protein re-surfacing of E. coli L-Asparaginase to evade pre-existing anti-drug antibodies and hypersensitivity responses
por: Bootwala, Ali, et al.
Publicado: (2022)

A Review of L-Asparaginase Hypersensitivity in Paediatric Acute Lymphoblastic Leukaemia Patients with Regard to the Measurement of Anti-Asparaginase Antibodies and Their Genetic Predisposition
por: Tan, Yan Qi, et al.
Publicado: (2023)

Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase
por: Modi, Tapasvi, et al.
Publicado: (2021)

A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro
por: Maggi, Maristella, et al.
Publicado: (2017)

Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F)
por: Ardalan, Noeman, et al.
Publicado: (2021)

The effects of PEGylation on LNP based mRNA delivery to the eye
por: Ryals, Renee C., et al.
Publicado: (2020)

Development of Escherichia coli Asparaginase II for Immunosensing: A Trade-Off between Receptor Density and Sensing Efficiency
por: Charbonneau, David M., et al.
Publicado: (2017)

Recombinant L-Asparaginase from Zymomonas mobilis: A Potential New Antileukemic Agent Produced in Escherichia coli
por: Einsfeldt, Karen, et al.
Publicado: (2016)

Production of PEGylated GCSF from Non-classical Inclusion Bodies Expressed in Escherichia coli
por: Trinh, Nguyen Thi My, et al.
Publicado: (2021)

Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
por: Möricke, Anja, et al.
Publicado: (2023)

Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity
por: Kutszegi, Nóra, et al.
Publicado: (2015)

Correction: Recombinant L-Asparaginase from Zymomonas mobilis: A Potential New Antileukemic Agent Produced in Escherichia coli
por: Einsfeldt, Karen, et al.
Publicado: (2016)

Deciphering Additional Roles for the EF-Tu, l-Asparaginase II and OmpT Proteins of Shiga Toxin-Producing Escherichia coli
por: Torres, Alexia N., et al.
Publicado: (2020)

Biomarkers of PEGylated Liposomal Doxorubicin-Induced Hypersensitivity Reaction in Breast Cancer Patients Based on Metabolomics
por: Zhuang, Wei, et al.
Publicado: (2022)

Opportunistic complexes of E. coli L-asparaginases with citrate anions
por: Lubkowski, Jacek, et al.
Publicado: (2019)

Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy
por: Van Trimpont, Maaike, et al.
Publicado: (2022)

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
por: Patel, B, et al.
Publicado: (2017)

Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data
por: Würthwein, Gudrun, et al.
Publicado: (2021)

Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli‐Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia
por: Vrooman, Lynda M., et al.
Publicado: (2015)

Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System
por: Crisafulli, Salvatore, et al.
Publicado: (2023)

Development of Processes for Recombinant L-Asparaginase II Production by Escherichia coli Bl21 (De3): From Shaker to Bioreactors
por: Barros, Thaís, et al.
Publicado: (2020)

Revealing Escherichia coli type II l-asparaginase active site flexible loop in its open, ligand-free conformation
por: Maggi, Maristella, et al.
Publicado: (2021)

Structural and biophysical studies of new l-asparaginase variants: lessons from random mutagenesis of the prototypic Escherichia coli Ntn-amidohydrolase
por: Loch, Joanna I., et al.
Publicado: (2022)

Expression and Biological Evaluation of an Engineered Recombinant L-asparaginase Designed by In Silico Method Based on Sequence of the Enzyme from Escherichia coli
por: Dastmalchi, Mahrokh, et al.
Publicado: (2023)

Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis
por: Dai, Zhan-Jing, et al.
Publicado: (2021)

Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase
por: Lorentz, Kristen M., et al.
Publicado: (2015)

Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach
por: Siebel, Christian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3qg4v82lfu7e9u2jcjsl31m2md